Technology Bundle ID

Novel In Vitro Granuloma Model for Studying Tuberculosis and Drug Efficacy

Linked ID
Lead Inventors
Frederick Quinn (CDC)
Kristin Birkness (CDC)
Manon Deslauriers (CDC)
Peter King (CDC)
Development Stages
Development Status
  • In vitro data available
  • Prototype
CDC researchers have developed an in vitro model system designed to simulate early-stage Mycobacterium tuberculosis infection and induced granuloma formation. This modeling platform can be used for studying tuberculosis pathogenicity, identifying phenotypically-interesting clinical isolates, studying early-stage host cytokine/chemokine responses, and in vitro candidate-drug screening. The approach incorporates autologous human macrophages, human peripheral blood mononuclear cells, and mycobacteria to mimic in situ granuloma formation in a controllable in vitro environment. This technology would be broadly useful for investigations into the numerous facets of early granuloma host-pathogen interaction, ultimately leading to improved prevention, intervention, and treatment strategies.
Commercial Applications
  • In vitro modeling system
  • Basic research into tuberculosis-host interactions
  • Drug candidate screening
Competitive Advantages
  • Low-cost alternative for modeling mycobacterial infections within complex tissue systems
  • Allows researchers to examine early-stage granuloma formation in a highly controllable, human-based modeling system
  • Cost-effective screening of potential therapeutic compounds and/or phenotypically-interesting mycobacteria

Request More Info

Licensing Contact: